Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1908 - Androgen Receptor (AR) Aberrations in Patients (Pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Treated With Apalutamide (APA) Plus Androgen Deprivation Therapy (ADT) in TITAN

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Tumour Site

Prostate Cancer

Presenters

Kim Chi

Citation

Annals of Oncology (2019) 30 (suppl_5): v325-v355. 10.1093/annonc/mdz248

Authors

K.N. Chi1, S. Thomas2, N. Agarwal3, F. Feng4, G. Attard5, A.W. Wyatt6, M. Gormley2, D.S. Ricci7, A. Lopez-Gitlitz8, K. Deprince9, J. Larsen10, W. Chen2, B. Miladinovic11, V. Naini11, S. Chowdhury12

Author affiliations

  • 1 Department Of Medical Oncology, BC Cancer, V5Z 4E6 - Vancouver/CA
  • 2 Department Of Oncology Translational Research, Janssen Research & Development, Spring House/US
  • 3 Huntsman Cancer Institute, University of Utah, 84112 - Salt Lake City/US
  • 4 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 94158 - San Francisco/US
  • 5 Research Department Of Oncology, Institute of Cancer Research, London/GB
  • 6 Vancouver Prostate Centre, University of British Columbia, V6H 3Z6 - Vancouver/CA
  • 7 Department Of Oncology Translational Research, Janssen Research & Development, 19477 - Spring House/US
  • 8 Department Of Clinical Oncology, Janssen Research & Development, Los Angeles/US
  • 9 Department Of Clinical Oncology, Janssen Research & Development, 2340 - Beerse/BE
  • 10 Department Of Clinical Oncology, Janssen Research & Development, Raritan/US
  • 11 Department Of Clinical Biostats, Janssen Research & Development, 92121 - San Diego/US
  • 12 Department Of Medical Oncology, Guy’s, King’s, and St. Thomas’ Hospitals, and Sarah Cannon Research Institute, SE1 9RT - London/GB

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1908

Background

TITAN evaluated APA vs placebo (PBO), + ADT, in pts with mCSPC. APA improved overall survival (OS [HR, 0.67; 95% CI, 0.51-0.89; p = 0.0053]) vs PBO. We evaluated AR aberrations at baseline (BL) and end of treatment (EOT) and assessed associations of EOT AR aberrations with outcomes in TITAN.

Methods

From 265 pt samples (APA, n = 116; PBO, n = 149) available for evaluation, a subset was analyzed for circulating tumor (ct)DNA and AR aberrations (ARv7, AR amplification, AR ligand binding domain mutations) from cell-free (cf)DNA and cfRNA using next-generation sequencing and PCR, respectively. Associations with OS and duration on first subsequent therapy were assessed.

Results

BL characteristics of pts were balanced between biomarker-positive groups. Among aberrations at BL, AR amplification was associated with longer duration of prior ADT (4.2 mo vs 1.6 mo, pts with vs without AR amplification; p = 0.034). ctDNA % and frequency of AR aberrations increased from BL to EOT. At EOT, ctDNA % was similar in APA and PBO groups (60% and 66%), and AR aberrations were less frequent with APA vs PBO (Table). Regardless of treatment group, OS was significantly shorter with detection of any AR aberration at EOT (OS: 2.7 [1.1-6.6], p = 0.0278, APA; 6.1 [1.9-20.3], p = 0.0007, PBO). Detection of any AR aberration at EOT was significantly associated with duration on first subsequent therapy (2.0 [1.0-4.0], p = 0.0386).Table:

883P Frequency of AR aberrations at BL and EOT

BLEOT
n, (n/N%)APA + ADTPBO + ADTAPA + ADTPBO + ADT
ARv72/15 (13)6/44 (14)9/46 (20)29/81 (36)
AR mutation004/46 (9)7/81 (9)
AR amplification1/15 (7)6/44 (14)19/46 (41)42/81 (52)
Any AR aberrationa3/15 (20)10/44 (23)22/46 (48)b54/81 (67)
a

Only pts with ARv7, AR amplification, and AR mutation measured are reported. bFrom Fisher’s exact test for comparison vs PBO, p = 0.04.

Conclusions

In TITAN, AR amplification at BL was associated with even brief ADT exposure. AR aberrations were fewer at EOT with APA vs PBO. Pts with AR aberrations at EOT had worse outcomes vs pts without. Taken together, these findings suggest that early APA + ADT provides long-term benefits vs ADT alone without increased acquisition of AR aberrations. The detailed biological mechanisms underlying these findings need to be further studied.

Clinical trial identification

NCT02489318.

Editorial acknowledgement

Larissa Belova, PhD, of Parexel.

Legal entity responsible for the study

Janssen Research & Development.

Funding

Janssen Research & Development.

Disclosure

K.N. Chi: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Essa; Advisory / Consultancy, Research grant / Funding (institution): Lilly/ImClone; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Tokai Pharmaceuticals; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Janssen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Advisory / Consultancy: Amgen; Advisory / Consultancy: Essa; Advisory / Consultancy, Research grant / Funding (institution): Lilly/ImClone; Research grant / Funding (institution): Bristol-Myers Squibb; Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Tokai Pharmaceuticals. S. Thomas: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. N. Agarwal: Advisory / Consultancy: Argos Therapeutics; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; EMD Serono; Exelixis; Foundation One Inc; Genentech/Roche; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Research grant / Funding (institution): Active Biotech; Amgen; AstraZeneca; Bavarian Nordic; Bayer; BN ImmunoTherapeutics; Bristol-Myers Squibb; Calithera Biosciences; Celldex; Eisai; Exelixis; Genentech; GlaxoSmithKline; Immunomedics; Janssen; Medivation; Merck; Newlink Geneti. F. Feng: Leadership role, Shareholder / Stockholder / Stock options: PFS Genomics; Advisory / Consultancy: Dendreon; Advisory / Consultancy: EMD Serono; Advisory / Consultancy: Janssen Oncology; Advisory / Consultancy: Ferring Pharmaceuticals; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Bayer HealthCare Pharmaceuticals; Advisory / Consultancy: Blue Earth Diagnostics; Advisory / Consultancy: Celgene; Advisory / Consultancy: Medivation/Astellas Pharma; Research grant / Funding (institution): Zenith Epigenetics; Licensing / Royalties, I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer; it is in the process of being licensed to PFS Genomics, a company that I helped found: Patents, Royalties, Other Intellectual Property. G. Attard: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Astellas Pharma; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses: Janssen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Medivation; Advisory / Consultancy, Travel / Accommodation / Expenses: Abbott Laboratories; Advisory / Consultancy: ESSA; Advisory / Consultancy: Janssen-Cilag; Advisory / Consultancy: Millennium; Advisory / Consultancy: Novartis; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Ventana Medical Systems; Advisory / Consultancy: Veridex; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Takeda; Research grant / Funding (institution): Arno Therapeutics; Licensing / Royalties: The Institute of Cancer Research Rewards to Inventors list of abiraterone acetate; Non-remunerated activity/ies, Other relationship: Institute of Cancer Research. A.W. Wyatt: Advisory / Consultancy: Genzyme; Speaker Bureau / Expert testimony, Research grant / Funding (institution): Janssen. M. Gormley: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. D.S. Ricci: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. A. Lopez-Gitlitz: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. K. Deprince: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. J. Larsen: Full / Part-time employment: Janssen; Shareholder / Stockholder / Stock options: Johnson & Johnson. W. Chen: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. B. Miladinovic: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. V. Naini: Full / Part-time employment: Janssen Research & Development; Shareholder / Stockholder / Stock options: Johnson & Johnson. S. Chowdhury: Honoraria (self), Advisory / Consultancy: Clovis Oncology; Advisory / Consultancy: Astellas Pharma; Advisory / Consultancy: Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Pfizer; Advisory / Consultancy: Janssen-Cilag; Honoraria (self): Novartis; Research grant / Funding (institution): Sanofi/Aventis.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.